Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Neulasta; Belgium: Neulasta; Czech Republic: Neulasta; Denmark: Neulasta; Estonia: Neulasta; Finland: Neulasta; France: Neulasta; Germany: Neulasta; Greece: Neulasta; Hungary: Neulasta; Ireland: Neulasta; Italy: Neulasta; Latvia: Neulasta; Lithuania: Neulasta; Luxembourg: Neulasta; Malta: Neulasta; Netherlands: Neulasta; Poland: Neulasta; Portugal: Neulasta; Romania: Neulasta; Slovakia: Neulasta; Spain: Neulasta; Sweden: Neulasta; UK: Neulasta.

North America

Canada: Neulasta; USA: Neulasta.

Latin America

Argentina: Neulastim; Mexico: Neulastim.

Drug combinations


Pegfilgrastim: C~849~H~1347~N~223~O~244~S~9~ (C~2~H~4~O)~n~. N-(3-Hydroxypropyl)methionylcolony-stimulating factor (human), 1-ether with α-methyl-ω-hydroxypoly(oxyethylene). CAS-208265-92-3.

Pharmacologic Category

Hematopoietic Agents; Colony Stimulating Factor. (ATC-Code: L03AA13).

Mechanism of action

Stimulates production, maturation, and activation of neutrophils. Pegfilgrastim activates neutrophils to increase both migration and cytotoxicity.

Therapeutic use

To decrease incidence of infection, by stimulation of granulocyte production, in patients with nonmyeloid malignancies receiving myelosuppressive therapy associated with significant risk of febrile neutropenia.

Pregnancy and lactiation implications

Animal studies demonstrated adverse effects and fetal loss. There are no adequate, well-controlled studies in pregnant women. Use only if potential benefit to mother justifies potential risk to fetus. Excretion in breast milk unknown (use caution).

Unlabeled use


Hypersensitivity to pegfilgrastim, filgrastim, E. coli-derived proteins, or any component of the formulation.

Warnings and precautions

Allergic reactions (anaphylaxis, skin rash, erythema, and urticaria) occurred. Acute respiratory distress syndrome reported. Rare cases of splenic rupture reported. May precipitate sickle cell crises in sickle cell disease. Pegfilgrastim should not be used in period 14 days before to 24 hours after administration of cytotoxic chemotherapy (potential sensitivity of rapidly-dividing myeloid cells to cytotoxic chemotherapy). 6 mg fixed dose should not be used in adolescents weighing <45 kg. Packaging (needle cover) contains latex. May potentially act as growth factor for any tumor type, particularly myeloid malignancies. Tumors of nonhematopoietic origin may have surface receptors for pegfilgrastim.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart